Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

Jenny D. Beebe, Jing Yuan Liu, Jian Ting Zhang

Research output: Contribution to journalReview article

35 Scopus citations

Abstract

Signal transducer and activator of transcription 3 (STAT3) controls many biological processes including differentiation, survival, proliferation, and angiogenesis. In normal healthy cells, STAT3 is tightly regulated to maintain a momentary active state. However, aberrant or constitutively activated STAT3 has been observed in many different cancers and constitutively activated STAT3 has been shown to associate with poor prognosis and tumor progression. For this reason, STAT3 has been studied as a possible target in the treatment of many different types of cancers. However, despite decades of research, a FDA-approved STAT3 inhibitor has yet to emerge. In this review, we will analyze past studies targeting STAT3 for drug discovery, understand possible causes of failure in these studies, and provide potential insights for future efforts to overcome these roadblocks.

Original languageEnglish (US)
Pages (from-to)74-91
Number of pages18
JournalPharmacology and Therapeutics
Volume191
DOIs
StatePublished - Nov 2018

Keywords

  • STAT3 inhibitor
  • cancer therapeutics
  • clinical trials
  • drug discovery
  • molecular probes
  • small molecule compounds

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?'. Together they form a unique fingerprint.

  • Cite this